Open AccessHigh mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer
Author(s) -
Mikhail Gorbounov,
Neil Carleton,
Rebecca J Asch-Kendrick,
Lingling Xian,
Lisa M. Rooper,
Lionel Chia,
Ashley CiminoMathews,
Leslie Cope,
Alan K. Meeker,
Vered Stearns,
Robert W. Veltri,
Young Kyung Bae,
Linda Resar
Publication year - 2019
Publication title -
breast cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 154
eISSN - 1573-7217
pISSN - 0167-6806
DOI - 10.1007/s10549-019-05419-1
Subject(s) - breast cancer , estrogen receptor , oncology , estrogen , medicine , cancer , cancer research , biology
The high mobility group A1 (HMGA1) chromatin remodeling protein is required for metastatic progression and cancer stem cell properties in preclinical breast cancer models, although its role in breast carcinogenesis has remained unclear. To investigate HMGA1 in primary breast cancer, we evaluated immunoreactivity score (IRS) in tumors from a large cohort of Asian women; HMGA1 gene expression was queried from two independent Western cohorts.